Stéphane Giraudier Selected Research

Transforming Growth Factor beta1 (TGF beta 1)

7/2007	Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
1/2007	Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
6/2006	Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.
4/2005	Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression.
4/2003	Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.
11/2002	Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stéphane Giraudier Research Topics

Disease

10	Neoplasms (Cancer) 10/2022 - 08/2002
10	Primary Myelofibrosis (Myelosclerosis) 01/2011 - 10/2002
5	Fibrosis (Cirrhosis) 01/2018 - 11/2002
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2017 - 02/2003
4	Anemia 01/2021 - 07/2004
3	Polycythemia Vera 01/2022 - 01/2018
3	Thrombocytopenia (Thrombopenia) 01/2018 - 01/2015
3	Leukemia 09/2014 - 02/2003
3	Osteosclerosis 07/2007 - 04/2003
2	Polycythemia (Erythrocytosis) 01/2022 - 12/2018
2	Acute Promyelocytic Leukemia 01/2021 - 11/2005
2	Inflammation (Inflammations) 09/2018 - 01/2018
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 11/2002
2	Bone Marrow Failure Disorders 09/2012 - 06/2010
2	Proteinuria 09/2012 - 03/2005
2	Methylenetetrahydrofolate reductase deficiency 02/2011 - 07/2003
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 02/2010 - 07/2007
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2005 - 07/2004
1	Hemorrhage 12/2021
1	Musculoskeletal Pain 11/2019
1	Sarcoidosis (Schaumann Disease) 12/2018
1	Heart Failure 01/2018
1	Sepsis (Septicemia) 01/2018
1	Septic Shock (Toxic Shock Syndrome) 01/2018
1	Essential Thrombocythemia 01/2018
1	Hyperhomocysteinemia 03/2016
1	Pneumonia (Pneumonitis) 02/2016
1	Emphysema 02/2016
1	Disease Progression 02/2016
1	Neutropenia 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2014
1	Hyperplasia 10/2013
1	Intrinsic Factor Deficiency 09/2012
1	Methylmalonic acidemia 02/2011
1	Polyploidy 09/2010
1	Hemosiderosis 04/2010
1	Pulmonary Hypertension 01/2007

Drug/Important Bio-Agent (IBA)

8	Thrombopoietin (c-mpl Ligand)IBA 01/2018 - 11/2002
8	CytokinesIBA 01/2018 - 11/2002
6	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2002
6	Transforming Growth Factor beta1 (TGF beta 1)IBA 07/2007 - 11/2002
4	Biological ProductsIBA 12/2021 - 07/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 10/2002
3	Methionine (L-Methionine)FDA Link 09/2012 - 06/2010
3	HomocysteineIBA 09/2012 - 07/2003
2	Erythropoietin FDA Link 01/2022 - 07/2004
2	Tyrosine Kinase InhibitorsIBA 11/2019 - 11/2017
2	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 12/2014 - 09/2012
2	Folic Acid (Vitamin M)FDA LinkGeneric 12/2014 - 02/2011
2	Methylmalonic AcidIBA 09/2012 - 06/2010
2	Thrombopoietin ReceptorsIBA 07/2010 - 02/2010
2	OsteoprotegerinIBA 07/2007 - 04/2003
2	Imatinib Mesylate (Gleevec)FDA Link 03/2003 - 02/2003
1	ArsenicIBA 01/2021
1	Arsenic Trioxide (Trisenox)FDA Link 01/2021
1	InterferonsIBA 01/2021
1	ruxolitinibIBA 12/2018
1	Interferon-alpha (Interferon Alfa)IBA 10/2018
1	von Willebrand FactorIBA 09/2018
1	P-SelectinIBA 09/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2018
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2018
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2018
1	nilotinib FDA Link 03/2016
1	Transcription Factors (Transcription Factor)IBA 02/2016
1	Heme Oxygenase-1IBA 02/2016
1	Caspase 3 (Caspase-3)IBA 02/2016
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 02/2016
1	Pancreatic Elastase (Elastase)IBA 02/2016
1	Vitamin K FDA Link 02/2016
1	Matrix Metalloproteinase 12IBA 02/2016
1	NAD(P)H Dehydrogenase (Quinone) (Quinone Reductase)IBA 02/2016
1	ChemokinesIBA 02/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2015
1	Alanine Transaminase (SGPT)IBA 01/2015
1	Dasatinib (BMS 354825)FDA Link 10/2013
1	Immunoglobulin D (IgD)IBA 09/2012
1	5,10-methylenetetrahydrofolic acidIBA 02/2011
1	methionine synthase reductaseIBA 02/2011
1	Betaine (C.B.B.)FDA Link 02/2011
1	Hydroxocobalamin FDA Link 02/2011
1	Oxidoreductases (Dehydrogenase)IBA 02/2011
1	5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase (Methyltetrahydrofolate Homocysteine Methyltransferase)IBA 02/2011
1	Thrombospondin 1IBA 01/2011
1	MicroRNAs (MicroRNA)IBA 07/2010
1	Ferritins (Ferritin)IBA 04/2010
1	Chelating AgentsIBA 04/2010
1	Deferasirox FDA Link 04/2010
1	IronIBA 04/2010
1	Tyrosine (L-Tyrosine)FDA Link 02/2010
1	Bortezomib (Velcade)FDA Link 07/2007
1	Proteasome InhibitorsIBA 07/2007
1	MonocrotalineIBA 01/2007

Therapy/Procedure

5	Therapeutics 01/2021 - 07/2004
2	Drug Therapy (Chemotherapy) 12/2021 - 01/2018
2	Hemodilution 01/2021 - 01/2018
2	Transplantation 01/2020 - 11/2002
1	Hematopoietic Stem Cell Transplantation 01/2020
1	Chelation Therapy (Therapy, Chelation) 04/2010